Potential Future Approaches to Neoadjuvant and Adjuvant Immunotherapy for MIBC

The approval is supported by findings from the phase 3 ENVISION trial.

In this episode, Ashish M. Kamat, MD, MBBS, highlights the state of bladder cancer care in recognition of Bladder Cancer Awareness Month.

"As urologists, we are the gatekeepers, and we must always perform the best possible surgery to optimize oncological outcomes," writes Jeremy Teoh, MBBS, FRCSEd (Urol), FCSHK, FHKAM (Surgery).

“It's not a replacement for clinical judgment, obviously. But at the end of the day, the idea is that it shows you what your next steps are based on what the American Urological Association and [Society of Urologic Oncology] guidelines are for non-muscle invasive bladder cancer,” Chad R. Ritch, MD, MBA, FACS.

A recap of the FDA submissions and regulatory decisions in urology from May 2025.

The findings also lend further credence to the muscle-invasive bladder cancer treatment regimen, investigators reported.